RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Outperform and raises the price target from $34 to $35.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.